Bulks List
The FDA's list of substances permitted for compounding under Section 503A — the list that determines which peptides are legally compoundable.
Definition
The FDA Bulks List (under Section 503A of the FD&C Act) names substances that may be used by 503A compounding pharmacies when no FDA-approved drug product containing the substance is commercially available. HHS announced in February 2026 that ~14 peptides were being reclassified back to compounding-eligible status; the FDA's advisory committee meets in July 2026 for further guidance on the list.
Read More
FDAFood and Drug Administration
The US regulatory body for drugs, devices and compounding pharmacies — the agency that classifies which peptides may be compounded.
Pharmacy & Regulation503A Pharmacy
A US compounding pharmacy that prepares medications for individual patients based on a specific prescription.
Pharmacy & RegulationCompounded Peptide
A peptide prepared for an individual patient by a licensed compounding pharmacy, prescribed by a clinician and tested for identity, potency and contamination.
$149 panel.
A clinician reads it in 24 hours.
Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.